Database Query Results : Atorvastatin, Dipyridamole,

ATV, Atorvastatin: Click to Expand ⟱
Features: Statin
Atorvastatin is a statin, i.e., an inhibitor of HMG-CoA reductase, the rate-limiting enzyme of the mevalonate pathway. Clinically it is prescribed to lower LDL cholesterol and cardiovascular risk.

Atorvastatin — a synthetic small-molecule statin that competitively inhibits HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate (MVA) pathway. It is a clinically approved oral lipid-lowering drug (LDL-C reduction; ASCVD risk reduction) with extensive hepatic first-pass handling and pleiotropic vascular/anti-inflammatory effects. Classification: small-molecule drug; HMG-CoA reductase inhibitor (statin). Standard abbreviation(s): ATV; (brand: Lipitor). In oncology research, its main leverage is MVA-pathway suppression leading to reduced isoprenoid supply (FPP/GGPP) and impaired prenylation-dependent signaling (Ras/Rho family), with context-dependent chemosensitization/radiosensitization reported in preclinical and limited clinical settings.

Primary mechanisms (ranked):

  1. HMGCR inhibition → ↓ mevalonate flux → ↓ FPP/GGPP isoprenoids → impaired protein prenylation (Ras/Rho/Rac signaling dependence)
  2. ↓ prenylation/↓ lipid-raft cholesterol support → attenuation of growth, survival, EMT/migration programs (context-dependent)
  3. Compensatory sterol-feedback rewiring (SREBP2-driven upregulation of MVA genes; “restore-the-pathway” resistance axis)
  4. Immuno-inflammatory modulation (often ↓ NF-κB–linked cytokine programs; tumor-context dependent)
  5. Cell-stress outputs (apoptosis/autophagy modulation; mitochondrial stress/ROS changes in some models)
  6. Therapy interaction phenotypes (chemosensitization and radiosensitization in selected contexts; not universal)

Bioavailability / PK relevance: Oral dosing with high hepatic extraction; exposure is strongly interaction-sensitive because atorvastatin is a CYP3A4 substrate and also uses hepatic transport (e.g., OATP1B1/1B3). Clinically meaningful systemic levels are achievable, but many anticancer in-vitro concentrations may exceed typical free plasma exposures; tumor delivery and intracellular “on-pathway” inhibition are therefore context- and dosing-dependent.

In-vitro vs systemic exposure relevance: Antiproliferative/EMT and apoptosis effects in cell culture are frequently reported at micromolar concentrations, which may be higher than unbound systemic exposures in humans; the most translatable mechanism is on-target MVA suppression with downstream prenylation stress, especially where tumors are MVA-addicted or combined with agents that block feedback/compensation.

Clinical evidence status: Approved drug for dyslipidemia/ASCVD prevention. In cancer: extensive preclinical literature plus observational associations; limited interventional oncology studies exist (including biomarker-focused trials and combination/adjunct concepts). Overall status: repurposing candidate with context-dependent signals; not an established anticancer therapy.

Across preclinical and observational contexts, atorvastatin tends to:
-DOWNREGULATE proliferative and survival signaling (via impaired prenylation)
-REDUCE inflammatory signaling (NF-κB–linked effects)
-MODULATE immune and stromal interactions
-SENSITIZE some tumors to chemotherapy or radiation (context-dependent)
-Epidemiologic studies suggest statin use is associated with reduced incidence or improved outcomes in some cancers (e.g., colorectal, prostate, breast).

Atorvastatin — cancer-relevant mechanistic axes (ranked)

Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Mevalonate pathway suppression HMGCR ↓ → MVA flux ↓ HMGCR ↓ (hepatic target) P/R Depletes sterols + isoprenoids upstream On-target mechanism; anticancer relevance rises in MVA-addicted tumors and when combined with strategies that prevent compensation.
2 Protein prenylation stress Ras/Rho/Rac prenylation ↓ → signaling output ↓ Variable; typically tolerated at clinical doses R Disrupts membrane localization of key GTPases Central downstream effector of anticancer activity; impacts proliferation, migration, cytoskeletal dynamics, and survival programs.
3 SREBP2 feedback and “restore-the-pathway” resistance SREBP2 ↑ (often) → HMGCR/MVA genes ↑ (adaptive) SREBP2 ↑ (homeostatic lipid control) G Adaptive rewiring that can blunt efficacy Common translational constraint: tumors may upregulate MVA pathway, increase uptake, or rewire metabolism to bypass blockade.
4 Growth and survival signaling PI3K–AKT ↔/↓, MAPK ↔/↓ (model-dependent) Endothelial survival ↔/↑ (context-dependent) R/G Downshifts pro-survival signaling tone Often secondary to prenylation/lipid-raft disruption; direction depends on oncogenic wiring and dose.
5 Migration, invasion, EMT EMT ↓, motility ↓ (often) Wound/repair migration ↔ G Anti-migratory / anti-invasive phenotype Mechanistically linked to Rho-family prenylation and cytoskeletal/ECM programs; may be clinically relevant in select settings.
6 Inflammation and NF-κB-linked cytokine programs IL-6/IL-8/TNF-α ↓ (often) Vascular inflammation ↓ R/G Anti-inflammatory immunometabolic shift Pleiotropic statin effects; may affect tumor microenvironment and therapy tolerance, but tumor-immune direction can be context-dependent.
7 ROS and mitochondrial stress ROS ↑ (sometimes; dose-dependent) Oxidative injury ↔/↓ in vascular contexts P/R Stress signaling that can promote apoptosis or sensitize to therapy Reported in subsets of models; not universally primary. Separate “cancer cell ROS ↑” from “vascular protective” pleiotropy.
8 Cell death programs Apoptosis ↑; autophagy ↔/↑ (model-dependent) Generally cytoprotective at therapeutic dosing R/G Stress-induced cell fate shift Often downstream of prenylation deficit + metabolic stress; strong effects often require higher concentrations or combinations.
9 Drug transport and resistance P-gp ↓ (reported); efflux ↔/↓ (context-dependent) Transporter effects ↔ R/G Potential bioenhancement / chemosensitization May contribute to combination effects, but clinical relevance is uncertain and interaction risk must be managed.
10 Radiosensitization and chemosensitization RadioS ↑; ChemoSen ↑ (subset) Normal tissue injury ↔/↓ (some contexts) G Adjunct therapy leverage (context-dependent) Signals exist in preclinical and limited clinical/biomarker work; not a class-wide guarantee and may depend on tumor MVA reliance.
11 Clinical Translation Constraint Free exposure may be below many in-vitro “kill” concentrations; adaptive SREBP2 feedback; tumor heterogeneity Myopathy/rhabdomyolysis risk ↑ with interacting drugs; hepatic enzyme elevations; pregnancy contraindication — Defines practical therapeutic window Major constraints: CYP3A4/transport interactions (e.g., strong inhibitors; grapefruit), muscle toxicity risk, and uncertain tumor delivery/on-target engagement at tolerated doses.

TSF legend: P: 0–30 min   R: 30 min–3 hr   G: >3 hr
Dipy, Dipyridamole: Click to Expand ⟱
Features:
Dipyridamole is a medication primarily used for its antiplatelet and vasodilatory effects.(cardiovascular) Dipyridamole is primarily known as a phosphodiesterase inhibitor and anti‐platelet agent.

Mechanism: Dipyridamole inhibits phosphodiesterases (PDEs), enzymes that break down cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP).
Cancer Relevance: Increased cyclic nucleotide levels can affect cell proliferation, apoptosis, and differentiation. Elevated cAMP, for example, may contribute to growth arrest or modify signaling cascades in certain cancer cells.

• Dipyridamole has been observed in some studies to exert antioxidant effects.
• There is evidence—albeit less definitive in some cases—that dipyridamole might influence mitochondrial function, potentially altering the balance between ROS production and detoxification.

• By stabilizing mitochondrial membranes or affecting mitochondrial signaling pathways, dipyridamole could reduce the likelihood of excessive ROS generation.

Current literature does not provide strong evidence that dipyridamole directly inhibits the mevalonate pathway??
A) Nucleoside Salvage Blockade
-Tumors often rely on nucleoside salvage under stress.
-Dipyridamole blocks nucleoside uptake → replication stress and DNA synthesis pressure, especially when de novo synthesis is compromised.

B) Metabolic Stress & Redox Effects
-Interferes with PPP/NADPH support in certain contexts.
-Can sensitize cells to oxidative and metabolic stress, tipping stressed tumors toward death.

C) Adenosine Signaling Modulation
-By altering extracellular/intracellular adenosine handling, dipyridamole can modify immune and stress signaling in the tumor microenvironment (context-dependent).

-Chemo-sensitizer (adjunct)	Yes (experimental)
-Chemopreventive candidate	Yes (preclinical/observational)


Scientific Papers found: Click to Expand⟱
4985- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin-Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, SK-MEL-28 - in-vitro, BC, MDA-MB-435
HMG-CoA↓, SREBP2↓, eff↑, HMGCR⇅, ChemoSen↑,
4986- ATV,  Dipy,    The combination of statins and dipyridamole is effective preclinically in AML, MM, and breast cancer
- Review, Var, NA
HMG-CoA↓, AntiAg↑, eff↑, Apoptosis↑, selectivity↑, *toxicity↓, TumCG↓, PDE4↓, other↑,
4988- ATV,  Dipy,    Repurposing of the Cardiovascular Drug Statin for the Treatment of Cancers: Efficacy of Statin–Dipyridamole Combination Treatment in Melanoma Cell Lines
- in-vivo, Melanoma, NA
HMGCR↓, SREBP2↑, SREBP2↓, AntiAg↑,
4983- Dipy,  ATV,    Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one
- Review, Var, NA
HMG-CoA↓, AntiTum↓, eff↑,
4984- Dipy,  ATV,    Immediate Utility of Two Approved Agents to Target Both the Metabolic Mevalonate Pathway and Its Restorative Feedback Loop
- in-vitro, AML, NA
eff↑, Apoptosis↑, selectivity↑, TumCG↓, HMG-CoA↓, HMGCR↑,
4987- Dipy,  ATV,    Enhanced cardioprotection against ischemia-reperfusion injury with a dipyridamole and low-dose atorvastatin combination
- in-vivo, Nor, NA
*cardioP↑, *Akt↑, *eNOS↑,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Core Metabolism/Glycolysis ⓘ

HMG-CoA↓, 4,   SREBP2↓, 2,   SREBP2↑, 1,  

Cell Death ⓘ

Apoptosis↑, 2,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HMGCR↓, 1,   HMGCR↑, 1,   HMGCR⇅, 1,   TumCG↓, 2,  

Migration ⓘ

AntiAg↑, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 4,   selectivity↑, 2,  

Functional Outcomes ⓘ

AntiTum↓, 1,   PDE4↓, 1,  
Total Targets: 15

Pathway results for Effect on Normal Cells:


Cell Death ⓘ

Akt↑, 1,  

Angiogenesis & Vasculature ⓘ

eNOS↑, 1,  

Functional Outcomes ⓘ

cardioP↑, 1,   toxicity↓, 1,  
Total Targets: 4

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:2  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page